Stereotaxis, Inc. (STXS) AMEX
1.78
-0.1(-5.32%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.78
-0.1(-5.32%)
Currency In USD
| Previous Close | 1.88 |
| Open | 1.87 |
| Day High | 1.87 |
| Day Low | 1.77 |
| 52-Week High | 3.59 |
| 52-Week Low | 1.7 |
| Volume | 564,968 |
| Average Volume | 420,533 |
| Market Cap | 173.97M |
| PE | -7.42 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.91 |
| Moving Average 200 Days | 2.38 |
| Change | -0.1 |
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
GlobeNewswire Inc.
Feb 12, 2026 2:00 PM GMT
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth qua
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
GlobeNewswire Inc.
Feb 09, 2026 1:06 PM GMT
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klini
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
GlobeNewswire Inc.
Jan 06, 2026 1:01 PM GMT
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval f